Evidence map›Paper›PMID 37166497›Full record

ArticleEuropean radiology2023

Chest CT opportunistic biomarkers for phenotyping high-risk COVID-19 patients: a retrospective multicentre study.

Anna Palmisano, Chiara Gnasso, Alberto Cereda, Davide Vignale, Riccardo Leone, Valeria Nicoletti, Simone Barbieri, Marco Toselli, Francesco Giannini, Marco Loffi and 15 more

Registry-linked trialOpen access · hybridAbstract readMulticenter Study
In one paragraph

Article in European radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06537934 (Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases), which is not on this map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06537934 recruitingnot on this mapstarted 2024, after this paper: background citation

Advanced Mutidimensional and Ultra High Resolution Computed Tomography to Inspect Cardiopulmonary Involvement in Progressive Fibrosing Interstitial Lung Diseases

TypeobservationalSponsorIRCCS San RaffaeleRan2024 to 2026Enrolled123ConditionsInterstitial Lung Diseases
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 6 citations in OpenAlex.

  1. Pooled it
  2. The effects of SARS-CoV-2 on bone homeostasis.Frontiers in endocrinology · 2026
    Review
  3. Article
  4. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 13 institutions in 1 country.

Anna PalmisanoExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Chiara GnassoExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Alberto CeredaGVM Care & Research Maria Cecilia Hospital, Cotignola, Italy.
Davide VignaleExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Riccardo LeoneExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Valeria NicolettiExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Simone BarbieriExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy.
Marco ToselliGVM Care & Research Maria Cecilia Hospital, Cotignola, Italy.
Francesco GianniniGVM Care & Research Maria Cecilia Hospital, Cotignola, Italy.
Marco LoffiOspedale Di Cremona, Cremona, Italy.
Gianluigi PatelliASST Bolognini Hospital, Bergamo Est, Italy.
Alberto MonelloGuglielmo da Saliceto Hospital, Piacenza, Italy.
Gianmarco IannopolloOspedale Maggiore, Bologna, Italy.
Davide IppolitoSan Gerardo Hospital, Monza, Italy.
Elisabetta Maria ManciniCentro Cardiologico Monzino IRCCS, Milan, Italy.
Gianluca PontoneCentro Cardiologico Monzino IRCCS, Milan, Italy.
Luigi VignaliParma University Hospital, Parma, Italy.
Elisa ScarnecchiaASST Valtellina and Alto Lario, Eugenio Morelli Hospital, Sondalo, Italy.
Mario IannacconeSan Giovanni Bosco Hospital, ASL Città Di Torino, Turin, Italy.
Lucio BaffoniCasa Di Cura Villa Dei Pini, Civitanova Marche, Italy.
Massimiliano SpernadioICC Istituto Clinico Casalpalocco, Rome, Italy.
Caterina Chiara de CarliniSan L. Mandic Hospital, Merate, Italy.
Sandro SironiASST Papa Giovanni XXIII, Bergamo, Italy.
Claudio RapezziAzienda Ospedaliero-Universitaria Di Ferrara, Cona, FE, Italy.
Antonio EspositoExperimental Imaging Center, IRCCS San Raffaele Scientific Institute, Via Olgettina 60, Milan, Italy. esposito.antonio@hsr.it.ORCID http://orcid.org/0000-0002-1170-6266
Vita-Salute San Raffaele University · ITMaria Cecilia Hospital · ITCentro Cardiologico Monzino · ITAzienda Ospedaliera Bolognini Seriate · ITAzienda Ospedaliera San Gerardo · ITGuglielmo da Saliceto Hospital · ITIstituti Ospitalieri di Cremona · ITIstituto di Sessuologia Clinica · ITOspedale Eugenio Morelli · ITOspedale Maggiore Carlo Alberto Pizzardi · ITOspedale Papa Giovanni XXIII · ITOspedale San Giovanni Bosco · ITUniversity of Parma · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the value of opportunistic biomarkers derived from chest CT performed at hospital admission of COVID-19 patients for the phenotypization of high-risk patients.

methodsIn this multicentre retrospective study, 1845 consecutive COVID-19 patients with chest CT performed within 72 h from hospital admission were analysed. Clinical and outcome data were collected by each center 30 and 80 days after hospital admission. Patients with unknown outcomes were excluded. Chest CT was analysed in a single core lab and behind pneumonia CT scores were extracted opportunistic data about atherosclerotic profile (calcium score according to Agatston method), liver steatosis (≤ 40 HU), myosteatosis (paraspinal muscle F < 31.3 HU, M < 37.5 HU), and osteoporosis (D12 bone attenuation < 134 HU). Differences according to treatment and outcome were assessed with ANOVA. Prediction models were obtained using multivariate binary logistic regression and their AUCs were compared with the DeLong test.

resultsThe final cohort included 1669 patients (age 67.5 [58.5-77.4] yo) mainly men 1105/1669, 66.2%) and with reduced oxygen saturation (92% [88-95%]). Pneumonia severity, high Agatston score, myosteatosis, liver steatosis, and osteoporosis derived from CT were more prevalent in patients with more aggressive treatment, access to ICU, and in-hospital death (always p < 0.05). A multivariable model including clinical and CT variables improved the capability to predict non-critical pneumonia compared to a model including only clinical variables (AUC 0.801 vs 0.789; p = 0.0198) to predict patient death (AUC 0.815 vs 0.800; p = 0.001).

conclusionOpportunistic biomarkers derived from chest CT can improve the characterization of COVID-19 high-risk patients. CLINICAL RELEVANCE STATEMENT: In COVID-19 patients, opportunistic biomarkers of cardiometabolic risk extracted from chest CT improve patient risk stratification. KEY POINTS: • In COVID-19 patients, several information about patient comorbidities can be quantitatively extracted from chest CT, resulting associated with the severity of oxygen treatment, access to ICU, and death. • A prediction model based on multiparametric opportunistic biomarkers derived from chest CT resulted superior to a model including only clinical variables in a large cohort of 1669 patients suffering from SARS- CoV2 infection. • Opportunistic biomarkers of cardiometabolic comorbidities derived from chest CT may improve COVID-19 patients' risk stratification also in absence of detailed clinical data and laboratory tests identifying subclinical and previously unknown conditions.

Indexed as

Cardiovascular DiseasesCOVID-19Fatty LiverOsteoporosisAgedBiomarkersFemaleHospital MortalityHumansMaleRetrospective StudiesSARS-CoV-2Tomography, X-Ray ComputedBiomarkersComputed tomographyCoronary artery diseaseCOVID-19Fatty liverSarcopenia

Identifiers

PMID37166497
PMCPMC10173240
OpenAlexW4376133204

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.